Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Review Article

High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease

verfasst von: Derek G. Power, Timothy R. Asmis, Laura H. Tang, Karen Brown, Nancy E. Kemeny

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

A 72-year-old man was diagnosed with a poorly differentiated hepatic flexure mass seen on routine screening colonoscopy. He underwent a right hemicolectomy and biopsy of a liver lesion noted at laparotomy. Pathology revealed a high-grade neuroendocrine carcinoma in the primary tumor and the liver lesion. Post-operative imaging revealed an isolated FDG avid liver metastases which had not been appreciated pre-operatively. He was treated with combination platinum and etoposide for extensive stage small-cell carcinoma of the colon. After 6 cycles of chemotherapy, the isolated liver lesion remained FDG avid, albeit less than baseline. Radiofrequency ablation of the avid liver lesion was performed. Further, chemotherapy was given as the lesion remained FDG avid. Ablation was repeated and a subsequent biopsy was positive. Chemotherapy resumed for a total of 10 cycles. Repeat PET scan became negative and the patient remains disease-free 7 years from an initial diagnosis of extensive stage small-cell colon cancer with a negative PET scan. Aggressive locoregional treatment is an option in patients with extensive stage small-cell carcinoma of the colon who are left with an oligometastasis after platinum-based systemic chemotherapy.
Literatur
1.
Zurück zum Zitat Burke AB, Shekitka KM, Sobin LH. Small cell carcinomas of the large intestine. Am J Clin Pathol. 1991;95:315–21.PubMed Burke AB, Shekitka KM, Sobin LH. Small cell carcinomas of the large intestine. Am J Clin Pathol. 1991;95:315–21.PubMed
2.
Zurück zum Zitat Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47:163–9.PubMedCrossRef Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47:163–9.PubMedCrossRef
3.
Zurück zum Zitat Brenner B, Shah MA, Gonen M, et al. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer. 2004;90:1720–6.PubMed Brenner B, Shah MA, Gonen M, et al. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer. 2004;90:1720–6.PubMed
4.
Zurück zum Zitat Brenner B, Tang LH, Shia J, et al. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol. 2007;34:43–50.PubMedCrossRef Brenner B, Tang LH, Shia J, et al. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol. 2007;34:43–50.PubMedCrossRef
5.
Zurück zum Zitat Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719–31.PubMedCrossRef Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719–31.PubMedCrossRef
6.
Zurück zum Zitat Ho KJ, Herrera GA, Jones JM, Alexander CB. Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol. 1984;15:460–8.PubMedCrossRef Ho KJ, Herrera GA, Jones JM, Alexander CB. Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol. 1984;15:460–8.PubMedCrossRef
7.
Zurück zum Zitat de Bruine AP, Wiggers T, Beek C, et al. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer. 1993;54:765–71.PubMedCrossRef de Bruine AP, Wiggers T, Beek C, et al. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer. 1993;54:765–71.PubMedCrossRef
8.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC et al. American Joint Committee on Cancer Staging Manual. American Joint Committee on Cancer Staging Manual, 7th ed 2010; ISBN: 978-0-387-88440-0. Edge SB, Byrd DR, Compton CC et al. American Joint Committee on Cancer Staging Manual. American Joint Committee on Cancer Staging Manual, 7th ed 2010; ISBN: 978-0-387-88440-0.
9.
Zurück zum Zitat Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer–what limits limited disease? Lung Cancer. 2002;37:271–6.PubMedCrossRef Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer–what limits limited disease? Lung Cancer. 2002;37:271–6.PubMedCrossRef
10.
Zurück zum Zitat Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228–36.PubMedCrossRef Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228–36.PubMedCrossRef
11.
Zurück zum Zitat Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–54.PubMedCrossRef Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–54.PubMedCrossRef
12.
Zurück zum Zitat Kut V, Spies W, Spies S, et al. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007;30:45–50.PubMedCrossRef Kut V, Spies W, Spies S, et al. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007;30:45–50.PubMedCrossRef
13.
Zurück zum Zitat NCCN. NCCN Clinical practice guidelines in oncology. National Comprehensive Cancer Network (NCCN) 2010; v10. NCCN. NCCN Clinical practice guidelines in oncology. National Comprehensive Cancer Network (NCCN) 2010; v10.
14.
Zurück zum Zitat Van Der Gaast A, Verwey J, Prins E, Splinter TA. Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer. 1990;65:422–4.CrossRef Van Der Gaast A, Verwey J, Prins E, Splinter TA. Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer. 1990;65:422–4.CrossRef
15.
Zurück zum Zitat Brennan SM, Gregory DL, Stillie A, et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer. 2010;116:888–95.PubMedCrossRef Brennan SM, Gregory DL, Stillie A, et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer. 2010;116:888–95.PubMedCrossRef
16.
Zurück zum Zitat Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer. 2007;110:1068–76.PubMedCrossRef Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer. 2007;110:1068–76.PubMedCrossRef
17.
Zurück zum Zitat Ku GY, Minsky BD, Rusch VW, et al. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol. 2008;19:533–7.PubMedCrossRef Ku GY, Minsky BD, Rusch VW, et al. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol. 2008;19:533–7.PubMedCrossRef
18.
Zurück zum Zitat Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.PubMedCrossRef Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.PubMedCrossRef
19.
Zurück zum Zitat Kelsen DP, Weston E, Kurtz R, et al. Small-cell carcinoma of the esophagus: treatment by chemotherapy alone. Cancer. 1980;45:1558–61.PubMedCrossRef Kelsen DP, Weston E, Kurtz R, et al. Small-cell carcinoma of the esophagus: treatment by chemotherapy alone. Cancer. 1980;45:1558–61.PubMedCrossRef
20.
Zurück zum Zitat Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.PubMedCrossRef Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.PubMedCrossRef
21.
Zurück zum Zitat Yachida S, Matsushita K, Usuki H, et al. Long-term survival after resection for small cell carcinoma of the esophagus. Ann Thorac Surg. 2001;72:596–7.PubMedCrossRef Yachida S, Matsushita K, Usuki H, et al. Long-term survival after resection for small cell carcinoma of the esophagus. Ann Thorac Surg. 2001;72:596–7.PubMedCrossRef
22.
Zurück zum Zitat Lee JM, Lee KB, Nam JH, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19:321–6.PubMedCrossRef Lee JM, Lee KB, Nam JH, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19:321–6.PubMedCrossRef
23.
Zurück zum Zitat Casas F, Ferrer F, Farrus B, et al. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997;80:1366–72.PubMedCrossRef Casas F, Ferrer F, Farrus B, et al. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997;80:1366–72.PubMedCrossRef
24.
Zurück zum Zitat Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond. Oncologist. 2001;6:66–80.PubMedCrossRef Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond. Oncologist. 2001;6:66–80.PubMedCrossRef
25.
Zurück zum Zitat Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.PubMedCrossRef Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.PubMedCrossRef
26.
Zurück zum Zitat Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.PubMedCrossRef Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.PubMedCrossRef
27.
Zurück zum Zitat Lara PN Jr, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006;7:353–6.PubMedCrossRef Lara PN Jr, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006;7:353–6.PubMedCrossRef
28.
Zurück zum Zitat Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237–48.PubMedCrossRef Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237–48.PubMedCrossRef
29.
Zurück zum Zitat Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin. 2004;14:271–81.PubMedCrossRef Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin. 2004;14:271–81.PubMedCrossRef
Metadaten
Titel
High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease
verfasst von
Derek G. Power
Timothy R. Asmis
Laura H. Tang
Karen Brown
Nancy E. Kemeny
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9674-1

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.